Navigation Links
Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
Date:3/4/2008

TUSTIN, Calif., March 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it will release its financial results for the third quarter of fiscal year 2008 on March 11, 2008 at 7:00 a.m. EDT and will host a conference call and webcast to discuss the results at 11:30 a.m. EDT on the same day.

Peregrine's senior management will discuss financial results for the quarter and will review recent operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the live or archived webcast.

The conference call and webcast will begin at 11:30 a.m. EDT/8:30 a.m. PDT.

To listen to a live broadcast of the call over the Internet or to review the archived webcast, please visit: http://www.peregrineinc.com. The webcast will be archived on Peregrine's website for 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: 1 (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through March 18, 2008 by calling (877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
2. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
3. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
4. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
8. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
9. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
10. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
11. SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... Cleveland, Ohio (PRWEB) April 27, 2015 ... execution of an agreement with Joslin Diabetes Center ... Phase 2b study of Diasome’s novel Hepatocyte Directed ... with Type 1 diabetes. , Located in ... research, clinical care and education organization dedicated to ...
(Date:4/27/2015)... , April 27, 2015 ... information products and services, and Qatar University Research Office   ... Scopus Awards. The awards ceremony, held last week ... , was attended by more than 40 guests representing ... awards were presented by Professor Sheikha Abdulla Al-Misnad , ...
(Date:4/24/2015)... Top student social innovators from the ... universities, including UCSD and SDSU, will pitch their impact ... national and nonprofit companies for an opportunity to win ... Social Innovation Challenge 2015 . , The 2015 Social ... addressing a diverse range of issues including poverty, education, ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 Leading ... milestones in its allogeneic stem-cell product development program ... properly reflect the corporate strategic direction. , “I ... (donor) adipose stem cell development program has been ... our cGMP manufacturing facility and hiring of our ...
Breaking Biology Technology:Diasome Pharmaceuticals Announces Clinical Trial Design Collaboration 2Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 2Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 3Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 4Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 55th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 25th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 3Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2
... Sensus Healthcare is proud to announce ... South Beach Symposium™ in Miami Beach, FL ... a comprehensive session with three non-overlapping tracks in clinical ... superficial radiotherapy (SRT) with their SRT-100™ advanced platform as ...
... YORK, Feb. 17, 2011 Reportlinker.com announces that ... its catalogue: Targeted Therapeutics- Advancement ... Drive the Market http://www.reportlinker.com/p0397055/Targeted-Therapeutics--Advancement-in-Gene-Therapy-and-Stem-Cell-Therapy-will-Drive-the-Market.html ... Therapy and Stem Cell Therapy will Drive the ...
... someday become one of the most effective weapons to stop ... of lives in Haiti since the devastating earthquake last year. ... would allow relief workers to test water sources that could ... sugar dextran is coated onto iron oxide nanoparticles and then ...
Cached Biology Technology:Sensus Healthcare Announces Its Exhibitor Attendance at the 9th Annual South Beach Symposium™ 2Reportlinker Adds Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market 2Reportlinker Adds Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market 3Special sugar, nanoparticles combine to detect cholera toxin 2Special sugar, nanoparticles combine to detect cholera toxin 3
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
(Date:4/2/2015)... BETHESDA, Md. , April 2, 2015 ... Salt Lake City , the American ... election of five new directors to its Board.  Members ... for the ACMG and for forming and advancing its ... the medical genetics profession. "It,s an eventful ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... in Yemen, is threatening livelihoods, in a country where rearing ... a Ministerial delegation was at the IAEA in Vienna, Austria, ... fight the deadly pest. The menacing fly lays its ... animal. The maggots then feast off the living flesh, and ...
... May 5 bioMETRX Inc., (OTC,Bulletin Board: BMRX), ... today announced that it has closed an interim,round ... of previous angel,accredited investors., "We have tremendous ... company has demonstrated to us the ability to ...
... a plant produces is closely tied to its sexual ... the evolution of such intimate relationships between plants and ... its kind and published online in the British Ecological ... recent dramatic decline in certain bumblebee species found in ...
Cached Biology News:Screw worm outbreak in Yemen 2Screw worm outbreak in Yemen 3bioMETRX, Inc. Closes Angel Round of Funding 2Ecologists tease out private lives of plants and their pollinators 2
... Product Goat polyclonal to Cholesterol Oxidase ... Reactivity / Specificity Cross-reacts with bacteria. ... Background Information Cholesterol oxidases exist as ... and are implicated in bacterial pathogenesis. In ...
Phospho-PERK (Thr980) Antibody...
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
Sheep polyclonal to Staphylococcus DNase ( Abpromise for all tested applications). Antigen: Full length native protein (purified)....
Biology Products: